- Foster City, California, United States
- On-site
- Full-time · Director
- $243K–$315K per year
- 12+ years
Own end-to-end biomarker and translational strategy across a portfolio of inflammatory bowel disease (IBD) and liver programs. This player-coach role requires recognized scientific expertise, demonstrated productivity and the ability to translate human biology and biomarker evidence into high-impact clinical development, regulatory and portfolio decisions.
Compensation
The salary range for this position is: $243,100.00 - $314,600.00. Gilead considers a variety of factors when determining base compensation, including experience, qualifications, and geographic location. These considerations mean actual compensation will vary. This position may also be eligible for a discretionary annual bonus, discretionary stock-based long-term incentives (eligibility may vary based on role), paid time off, and a benefits package.
Responsibilities
- Own and continuously evolve the integrated GI/IBD and liver biomarker and translational strategy across multiple clinical-stage assets, aligning evidence generation with disease-area, asset, regulatory and portfolio objectives.
- Lead the most complex programs from early clinical development through Phase II/III, defining decision criteria for target engagement, dose, proof-of-concept, patient selection, response, safety, differentiation and lifecycle opportunities.
- Provide hands-on scientific leadership for analysis and interpretation of blood, stool, intestinal and liver tissue, endoscopic, histologic, imaging, pathology and multi-omic datasets.
- Create cross-asset frameworks for forward and reverse translation, including integrated biopsy strategies and analyses of response, resistance, relapse, patient heterogeneity and mechanisms of action.
- Lead biomarker and translational contributions to protocols, analysis plans, investigator brochures, clinical study reports, briefing documents, regulatory submissions and health authority interactions.